Rapid Myco
1 known investors
Rapid-Myco Technologies (RMT) develops a patented phagomagnetic separation (PhMS)-qPCR diagnostic platform that uses bacteriophages to detect active mycobacterial infections in livestock and humans within about eight hours. The technology targets diseases such as bovine tuberculosis and Johne's disease in cattle, sheep and goats, and tuberculosis and leprosy in humans.
Investors · 1
Frequently asked questions
- What does Rapid Myco do?
- Rapid-Myco Technologies (RMT) develops a patented phagomagnetic separation (PhMS)-qPCR diagnostic platform that uses bacteriophages to detect active mycobacterial infections in livestock and humans within about eight hours. The technology targets diseases such as bovine tuberculosis and Johne's disease in cattle, sheep and goats, and tuberculosis and leprosy in humans.
- Who are Rapid Myco's investors?
- Rapid Myco's investors include Clarendon Fund Managers Ltd..